Navigation Links
China Pharma Holdings, Inc. to Report Second Quarter 2011 Financial Results on August 11, 2011
Date:8/3/2011

HAIKOU, China, Aug. 3, 2011 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it plans to release its second quarter 2011 financial results before the market opens on Thursday, August 11, 2011.

The Company will hold a conference call at 8:30 am ET on August 11, 2011 to discuss second quarter 2011 results. Listeners may access the call by dialing 1-866-831-6272 or 1-617-213-8859 for international callers, access code: 72860215. A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com. A replay of the call will be accessible through August 18, 2011 by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 99608603.

About China Pharma Holdings, Inc.China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com.Contact:China Pharma Holdings, Inc.Phone: +86-898-6681-1730 (China)Email: hps@chinapharmaholdings.com
'/>"/>

SOURCE China Pharma Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
2. China Kanghui Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011
3. China Nuvo Solar Target Acquisition SurgLine Announces Third-Party Distribution Agreement With OptiMedical, Corp.
4. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
5. PolyGel Signs Long Term Exclusive Agreement With Chinas Largest Distributor of Healthcare Products
6. China Cardiac Catheters and Guidewires - Market Trends Till 2016
7. Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
8. Infusion Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
9. China Nuvo Solar Announces Definitive Agreement Signed to Acquire Medical Products company SurgLine, Inc.
10. China Sky One Medical Wins Bidding Process on Land Use Rights Covering Land at Song Bei District in Harbin
11. China Medical Technologies Announces the Filing of its Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2011 with the SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... ... 2016 , ... VeloReality President and co-founder Gary ... VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the company's ... the weight of the unit, they also enhance the rider's experience with a ...
Breaking Medicine News(10 mins):